Overview

Study of Selumetinib (MK-5618) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (MK-5618-001)

Status:
Active, not recruiting

Trial end date:
2022-06-13

Target enrollment:

Participant gender:

Summary

This study will examine the safety, pharmacokinetics, and efficacy of escalating doses of selumetinib (MK-5618) in combination with intravenous (IV) pembrolizumab (MK-3475) for participants with advanced / metastatic solid tumors.

Phase:

Phase 1

Details

Lead Sponsor:

Merck Sharp & Dohme Corp.

Treatments:

Pembrolizumab